Now showing items 2520-2539 of 3378

    • Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. 

      Rescigno, P; Lorente, D; Bianchini, D; Ferraldeschi, R; Kolinsky, MP; Sideris, S; Zafeiriou, Z; Sumanasuriya, S; Smith, AD; Mehra, N; Jayaram, A; Perez-Lopez, R; Mateo, J; Parker, C; Dearnaley, DP; Tunariu, N; Reid, A; Attard, G; de Bono, JS (2016-11)
      The availability of multiple new treatments for metastatic castration-resistant prostate cancer (mCRPC) mandates earlier treatment switches in the absence of a response. A decline in prostate-specific antigen (PSA) is ...
    • Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. 

      Mikropoulos, C; Selkirk, CGH; Saya, S; Bancroft, E; Vertosick, E; Dadaev, T; Brendler, C; Page, E; Dias, A; Evans, DG; Rothwell, J; Maehle, L; Axcrona, K; Richardson, K; Eccles, D; Jensen, T; Osther, PJ; van Asperen, CJ; Vasen, H; Kiemeney, LA; Ringelberg, J; Cybulski, C; Wokolorczyk, D; Hart, R; Glover, W; Lam, J; Taylor, L; Salinas, M; Feliubadaló, L; Oldenburg, R; Cremers, R; Verhaegh, G; van Zelst-Stams, WA; Oosterwijk, JC; Cook, J; Rosario, DJ; Buys, SS; Conner, T; Domchek, S; Powers, J; Ausems, MG; Teixeira, MR; Maia, S; Izatt, L; Schmutzler, R; Rhiem, K; Foulkes, WD; Boshari, T; Davidson, R; Ruijs, M; Helderman-van den Enden, AT; Andrews, L; Walker, L; Snape, K; Henderson, A; Jobson, I; Lindeman, GJ; Liljegren, A; Harris, M; Adank, MA; Kirk, J; Taylor, A; Susman, R; Chen-Shtoyerman, R; Pachter, N; Spigelman, A; Side, L; Zgajnar, J; Mora, J; Brewer, C; Gadea, N; Brady, AF; Gallagher, D; van Os, T; Donaldson, A; Stefansdottir, V; Barwell, J; James, PA; Murphy, D; Friedman, E; Nicolai, N; Greenhalgh, L; Obeid, E; Murthy, V; Copakova, L; McGrath, J; Teo, S-H; Strom, S; Kast, K; Leongamornlert, DA; Chamberlain, A; Pope, J; Newlin, AC; Aaronson, N; Ardern-Jones, A; Bangma, C; Castro, E; Dearnaley, D; Eyfjord, J; Falconer, A; Foster, CS; Gronberg, H; Hamdy, FC; Johannsson, O; Khoo, V; Lubinski, J; Grindedal, EM; McKinley, J; Shackleton, K; Mitra, AV; Moynihan, C; Rennert, G; Suri, M; Tricker, K; IMPACT study collaborators; Moss, S; Kote-Jarai, Z; Vickers, A; Lilja, H; Helfand, BT; Eeles, RA (2018-01-04)
      BACKGROUND:Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition ...
    • Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. 

      Mikropoulos, C; Hutten Selkirk, CG; Saya, S; Bancroft, E; Vertosick, E; Dadaev, T; Brendler, C; Page, E; Dias, A; Evans, DG; Rothwell, J; Maehle, L; Axcrona, K; Richardson, K; Eccles, D; Jensen, T; Osther, PJ; van Asperen, CJ; Vasen, H; Kiemeney, LA; Ringelberg, J; Cybulski, C; Wokolorczyk, D; Hart, R; Glover, W; Lam, J; Taylor, L; Salinas, M; Feliubadaló, L; Oldenburg, R; Cremers, R; Verhaegh, G; van Zelst-Stams, WA; Oosterwijk, JC; Cook, J; Rosario, DJ; Buys, SS; Conner, T; Domchek, S; Powers, J; Ausems, MGEM; Teixeira, MR; Maia, S; Izatt, L; Schmutzler, R; Rhiem, K; Foulkes, WD; Boshari, T; Davidson, R; Ruijs, M; Helderman-van den Enden, ATJM; Andrews, L; Walker, L; Snape, K; Henderson, A; Jobson, I; Lindeman, GJ; Liljegren, A; Harris, M; Adank, MA; Kirk, J; Taylor, A; Susman, R; Chen-Shtoyerman, R; Pachter, N; Spigelman, A; Side, L; Zgajnar, J; Mora, J; Brewer, C; Gadea, N; Brady, AF; Gallagher, D; van Os, T; Donaldson, A; Stefansdottir, V; Barwell, J; James, PA; Murphy, D; Friedman, E; Nicolai, N; Greenhalgh, L; Obeid, E; Murthy, V; Copakova, L; McGrath, J; Teo, S-H; Strom, S; Kast, K; Leongamornlert, DA; Chamberlain, A; Pope, J; Newlin, AC; Aaronson, N; Ardern-Jones, A; Bangma, C; Castro, E; Dearnaley, D; Eyfjord, J; Falconer, A; Foster, CS; Gronberg, H; Hamdy, FC; Johannsson, O; Khoo, V; Lubinski, J; Grindedal, EM; McKinley, J; Shackleton, K; Mitra, AV; Moynihan, C; Rennert, G; Suri, M; Tricker, K; IMPACT study collaborators; Moss, S; Kote-Jarai, Z; Vickers, A; Lilja, H; Helfand, BT; Eeles, RA (2018-03-06)
      This corrects the article DOI: 10.1038/bjc.2017.429.
    • Prostate-specific antigen velocity in untreated, localized prostate cancer. 

      Venkitaraman, R; Norman, A; Woode-Amissah, R; Dearnaley, D; Horwich, A; Huddart, R; Parker, C (2008-01)
      OBJECTIVE: To report the results of a prospective study of active surveillance of untreated prostate cancer, with a focus on baseline predictors of prostate-specific antigen (PSA) velocity, as PSA velocity before treatment ...
    • Prostatic pathology reporting in the UK: development of a national external quality assurance scheme 

      Harnden, P; Coleman, D; Moss, S; Kodikara, S; Patnick, J; Melia, J (BLACKWELL PUBLISHING, 2008-01)
      Aims: To develop a baseline picture of prostatic pathology reporting in the UK, identify areas of particular difficulty and assess the feasibility of a national external quality assurance scheme based on prostatic biopsy ...
    • Protein and drug interactions in the minor groove of DNA 

      Moravek, Z; Neidle, S; Schneider, B (2002-03-01)
      Interactions between proteins, drugs, water and B-DNA minor groove have been analyzed in crystal structures of 60 protein-DNA and 14 drug-DNA complexes. It was found that only purine N3, pyrimidine O2, guanine N2 and ...
    • Protein assemblies with palindromic structure motifs 

      Pinotsis, N; Wilmanns, M (BIRKHAUSER VERLAG AG, 2008-10)
      Symmetric DNA sequence motifs allow the formation of palindromic protein/DNA complexes. Although symmetric protein sequence motifs are less common, recent structural discoveries have unraveled a few protein/protein complexes ...
    • Protein coalitions in a core mammalian biochemical network linked by rapidly evolving proteins 

      Ainali, C; Simon, M; Freilich, S; Espinosa, O; Hazelwood, L; Tsoka, S; Ouzounis, CA; Hancock, JM (BIOMED CENTRAL LTD, 2011-05-25)
      Background: Cellular ATP levels are generated by glucose-stimulated mitochondrial metabolism and determine metabolic responses, such as glucose-stimulated insulin secretion (GSIS) from the beta-cells of pancreatic islets. ...
    • Protein identification and quantification by two-dimensional infrared spectroscopy: Implications for an all-optical proteomic platform 

      Fournier, F; Gardner, EM; Kedra, DA; Donaldson, PM; Guo, R; Butcher, SA; Gould, IR; Willison, KR; Klug, DR (NATL ACAD SCIENCES, 2008-10-07)
      Electron-vibration-vibration two-dimensional coherent spectroscopy, a variant of 2DIR, is shown to be a useful tool to differentiate a set of 10 proteins based on their amino acid content. Two-dimensional vibrational ...
    • The proteolytic release of genotoxins from cooked beef 

      Martin, FL; Cole, KJ; Phillips, DH; Grover, PL (2002-05-24)
      Dietary factors are important in the aetiology of human cancer and carcinogens, mostly heterocyclic aromatic amines, have been isolated from cooked proteinaceous foodstuffs. Whilst such carcinogens have induced tumours in ...
    • Proteomic navigation using proximity-labeling. 

      Gentzel, M; Pardo, M; Subramaniam, S; Stewart, AF; Choudhary, JS (2019-07)
      The identification of bona fide protein-protein interactions and the mapping of proteomes was greatly enhanced by protein tagging for generic affinity purification methods and analysis by mass spectrometry (AP-MS). The ...
    • Proteomic research in sarcomas - current status and future opportunities. 

      Burns, J; Wilding, CP; L Jones, R; H Huang, P (2019-11-10)
      Sarcomas are a rare group of mesenchymal cancers comprising over 70 different histological subtypes. For the majority of these diseases, the molecular understanding of the basis of their initiation and progression remains ...
    • Proteomics and the search for biomarkers for renal cancer 

      Craven, RA; Vasudev, NS; Banks, RE (PERGAMON-ELSEVIER SCIENCE LTD, 2013-04)
      Worldwide, over 273,000 people are diagnosed with renal cancer each year. Approximately one third of patients present with locally advanced or metastatic disease and although surgery is largely curative in those with ...
    • Proteomics profiling of interactome dynamics by colocalisation analysis (COLA). 

      Mardakheh, FK; Sailem, HZ; Kümper, S; Tape, CJ; McCully, RR; Paul, A; Anjomani-Virmouni, S; Jørgensen, C; Poulogiannis, G; Marshall, CJ; Bakal, C (2016-12)
      Localisation and protein function are intimately linked in eukaryotes, as proteins are localised to specific compartments where they come into proximity of other functionally relevant proteins. Significant co-localisation ...
    • Proton Beam Therapy - the Challenges of Delivering High-quality Evidence of Clinical Benefit. 

      National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad) Proton Beam Clinical Trial Strategy Group (2018-05)
      The use of proton beam therapy (PBT) offers the opportunity to improve greater conformality of radiotherapy treatment delivery in some patients. However, it is associated with a high capital cost and the need to build new ...
    • Proton Therapy in Clinical Practice: Current Clinical Evidence 

      Brada, M; Pijls-Johannesma, M; De Ruysscher, D (American Society of Clinical Oncology, 2007-03-10)
    • PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer. 

      Otto, SJ; Moss, SM; Määttänen, L; Roobol, M; Zappa, M; Nelen, V; Kwiatkowski, M; Villers, A; Hugosson, J; Sanchez, AB; de Koning, HJ (2010-11)
      BACKGROUND: To describe the variation in PSA level by age group and screening round in the ERSPC centres and the variation in cancer detection rates in relation to the underlying prostate cancer incidence. METHODS: Individual ...
    • Psychological impact of genetic testing in women from high-risk breast cancer families 

      Meiser, B; Butow, P; Friedlander, M; Barratt, A; Schnieden, V; Watson, M; Brown, J; Tucker, K (2002)
      Psychological adjustment in 90 women (30 carriers and 60 non-carriers) who had undergone genetic testing for mutations in BRCA1 and BRCA2 breast/ovarian cancer susceptibility genes was compared with that of 53 women who ...
    • The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 6-month follow-up 

      Maissi, E; Marteau, TM; Hankins, M; Moss, S; Legood, R; Gray, A (NATURE PUBLISHING GROUP, 2005-03-28)
      State anxiety (S-STAI-6), distress (GHQ-12), concern and quality of life (EuroQoL-EQ-5D) 6 months after human papillomavirus (HPV) testing in women with borderline or mildly dyskaryotic smear test results were assessed ...
    • Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study 

      Maissi, E; Marteau, TM; Hankins, M; Moss, S; Legood, R; Gray, A (B M J PUBLISHING GROUP, 2004-05-29)
      Objective To describe the psychological impact on women of being tested for human papillomavirus (HPV) when smear test results are borderline or mildly dyskaryotic. Design Cross sectional questionnaire study. Setting Two ...